Investors / United States / Decheng Capital
Decheng Capital
Venture capital · Menlo Park, CA, United States · North America
Decheng Capital is an investment firm that provides capital and strategic support to early-stage life science companies and growth-stage healthcare companies. It was founded in 2012 and manages over $2.5 billion in assets.
Invests inHealthcare & Biotech
In its own wordslife scienceshealthcarebiotechtherapeuticsgene editing
Your fit with Decheng Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsDecheng Capital lists 50 checked portfolio companies on its own site and is named in 9 funding rounds, 6 of them as lead. Its most frequent entry is Series A, 50% of the companies with a known first round. Its largest themes are Healthcare & Biotech (98%) and Food & Agriculture (2%). 62% of its companies are based in United States. It invests most often alongside Foresite Capital, Casdin Capital and Lilly Asia Ventures.
Counts come from funding rounds that name Decheng Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Decheng Capital's whole history. Rounds on record name 8 companies; its own site lists 50. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 50% |
| Series B | 25% |
| Growth | 25% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 8 | 6 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 84th | 50 companies |
| Recent activity | 94th | 9 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 54th | 2% of companies confirmed by a round |
| Sector focus | 97th | 98% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Foresite Capital | 5 |
| Casdin Capital | 3 |
| Lilly Asia Ventures | 3 |
| Longitude Capital | 3 |
| Qiming Venture Partners | 3 |
| RA Capital | 3 |
| Vivo Capital | 3 |
| 8VC | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers4488%
- No longer answers00%
- Points to another company612%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 98% | 15% |
| Food & Agriculture | 2% | 3% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Foresite Capital
Compare Decheng Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Decheng Capital| Date | Company | Stage |
|---|---|---|
| 12 Nov 2026 | Series A Led | |
| 27 Sept 2026 | Series A Led | |
| 1 Jul 2026 | Series B Led | |
| 23 Jun 2026 | Series A | |
| 29 Apr 2026 | Series A Led | |
| 8 Apr 2026 | Series C+ | |
| 21 Nov 2025 | Series A |
Round details for Decheng Capital
Amounts, full round histories and every co-investor in Decheng Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
50 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Portfolio page | ||||
Healthcare & Biotech | Portfolio page | |||
| Adaptive Biotechnologies harnesses the adaptive immune system to unleash its power as a natural diagnostic and therapeutic tool to propel a paradigm shift in medicine | Healthcare & Biotech | Portfolio page | ||
| Adela delivers highly sensitive, blood-based tests that uncover critical insights from cell-free DNA for cancer detection and monitoring | Healthcare & Biotech | Portfolio page | ||
| Ak Medical is a company that develops and manufactures orthopedic products, including 3D printed implants and digitalized solutions for orthopedic treatment. | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Arcus Biosciences creates medicines by advancing validated biology with exceptional chemistry. | Healthcare & Biotech | Portfolio page | ||
| Ark Biosciences develops and commercializes innovative medicines for respiratory and pediatric diseases. | Healthcare & Biotech | Portfolio page | ||
| Baylor Genetics performs genetic testing and provides precision diagnostics | Healthcare & Biotech | Jul 2026Series B | Funding round | |
| BCFoods provides large-scale, industrial ingredients for food brands and manufacturers. | Food & Agriculture | Portfolio page | ||
| The company develops and tests immune-modulating therapies for cancer treatment. | Healthcare & Biotech | Portfolio page | ||
| Boundless Bio develops therapies for patients with intractable oncogene amplified cancers. | Healthcare & Biotech | Jun 2026Series A | Funding round | |
| Cellares manufactures cell therapies and provides related services and technologies | Healthcare & Biotech | Portfolio page | ||
| CG Oncology develops and delivers bladder-sparing immunotherapies for bladder cancer | Healthcare & Biotech | Portfolio page | ||
| Dragon Crown is a hi-tech enterprise integrating R&D, manufacture and sales of medical products | Healthcare & Biotech | Portfolio page | ||
| EpimAb Biotherapeutics develops innovative biopharmaceuticals using its proprietary bispecific antibody technology platform FIT-Ig | Healthcare & Biotech | Portfolio page | ||
| Equillium develops new products for severe autoimmune and inflammatory disorders | Healthcare & Biotech | Portfolio page | ||
| Everest Medicines is involved in the discovery, manufacturing and development of pharmaceutical products. | Healthcare & Biotech | Portfolio page | ||
| Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders | Healthcare & Biotech | Portfolio page | ||
| GRAIL develops and offers a multi-cancer early detection test that can screen for various types of cancer using a blood test. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- decheng.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 21 Nov 2025
- Companies checked
- 50
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Decheng Capital's profile as data
Pull Decheng Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/decheng.com
# also
GET /v1/firms/decheng.com/portfolio
GET /v1/firms/decheng.com/coinvestors
GET /v1/firms/decheng.com/news